Programmed death ligand 1 promotes early-life chlamydia respiratory infection-induced severe allergic airway disease

American Journal of Respiratory Cell and Molecular Biology

Volumn 54, Issue 4, 2016, Pages 493-503

  Starkey, Malcolm R ^a   Nguyen, Duc H ^a   Brown, Alexandra C ^a   Essilfie, Ama Tawiah ^a   Kim, Richard Y ^a   Yagita, Hideo ^b   Horvat, Jay C ^a   Hansbro, Philip M ^a  

^a UNIVERSITY OF NEWCASTLE   (Australia)

^b JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Airway hyperresponsiveness; Asthma; Chlamydia respiratory infection; Infant; PD L1

Indexed keywords

CD4 ANTIGEN; INTERLEUKIN 13; MESSENGER RNA; NEUTRALIZING ANTIBODY; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 LIGAND 2; CD274 PROTEIN, MOUSE; INTERLEUKIN 13 RECEPTOR ALPHA2; PDCD1 PROTEIN, MOUSE; PROGRAMMED DEATH 1 RECEPTOR;

ANIMAL EXPERIMENT; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHLAMYDIASIS; CONTROLLED STUDY; DENDRITIC CELL; DISEASE SEVERITY; FLOW CYTOMETRY; GENE EXPRESSION; HISTOPATHOLOGY; INFANT; LUNG FUNCTION; LUNG HOMOGENATE; LUNG WEIGHT; MONOCYTE; MOUSE; NONHUMAN; RESPIRATORY TRACT ALLERGY; RESPIRATORY TRACT INFECTION; ANIMAL; BAGG ALBINO MOUSE; COMPLICATION; DISEASE PREDISPOSITION; GENETICS; METABOLISM; PHYSIOLOGY; RESPIRATORY HYPERSENSITIVITY;

ANIMALS; ANTIGENS, CD274; CHLAMYDIA INFECTIONS; DISEASE SUSCEPTIBILITY; INTERLEUKIN-13 RECEPTOR ALPHA2 SUBUNIT; MICE; MICE, INBRED BALB C; PROGRAMMED CELL DEATH 1 RECEPTOR; RESPIRATORY HYPERSENSITIVITY; RESPIRATORY TRACT INFECTIONS; RNA, MESSENGER;

EID: 84963779025     PISSN: 10441549     EISSN: 15354989     Source Type: Journal    
DOI: 10.1165/rcmb.2015-0204OC     Document Type: Article

References (56)

1. Kuo CC, Jackson LA, Campbell LA, Grayston JT. Chlamydia pneumoniae (TWAR). Clin Microbiol Rev 1995;8: 451-461.
2. Grayston JT. Chlamydia pneumoniae, strain TWAR pneumonia. Annu Rev Med 1992;43:317-323.
3. Blasi F. Atypical pathogens and respiratory tract infections. Eur Respir J 2004;24:171-181.
4. Harrison HR, Taussig LM, Fulginiti VA. Chlamydia trachomatis and chronic respiratory disease in childhood. Pediatr Infect Dis 1982;1: 29-33.
5. Beagley KW, Huston WM, Hansbro PM, Timms P. Chlamydial infection of immune cells: Altered function and implications for disease. Crit Rev Immunol 2009;29:275-305.
6. Hansbro PM, Beagley KW, Horvat JC, Gibson PG. Role of atypical bacterial infection of the lung in predisposition/protection of asthma. Pharmacol Ther 2004;101:193-210.
7. Jupelli M, Guentzel MN, Meier PA, Zhong G, Murthy AK, Arulanandam BP. Endogenous IFN-g production is induced and required for protective immunity against pulmonary chlamydial infection in neonatal mice. J Immunol 2008;180:4148-4155.
8. Jupelli M, Selby DM, Guentzel MN, Chambers JP, Forsthuber TG, Zhong G, Murthy AK, Arulanandam BP. The contribution of interleukin-12/interferon-g axis in protection against neonatal pulmonary Chlamydia muridarum challenge. J Interferon Cytokine Res 2010;30:407-415.
9. Zaitsu M. Does Chlamydia pneumoniae infection trigger to development of asthma in wheezy infants? J Asthma 2009;46: 967-968.
10. Webley WC, Tilahun Y, Lay K, Patel K, Stuart ES, Andrzejewski C, Salva PS. Occurrence of Chlamydia trachomatis and Chlamydia pneumoniae in paediatric respiratory infections. Eur Respir J 2009; 33:360-367.
11. Webley WC, Salva PS, Andrzejewski C, Cirino F, West CA, Tilahun Y, Stuart ES. The bronchial lavage of pediatric patients with asthma contains infectious Chlamydia. Am J Respir Crit Care Med 2005;171: 1083-1088.
12. Hansbro PM, Starkey MR, Kim RY, Stevens RL, Foster PS, Horvat JC. Programming of the lung by early-life infection. J Dev Orig Health Dis 2012;3:153-158.
13. Hansbro PM, Kaiko GE, Foster PS. Cytokine/anti-cytokine therapy - novel treatments for asthma? Br J Pharmacol 2011;163:81-95.
14. Wills-Karp M, Luyimbazi J, Xu X, Schofield B, Neben TY, Karp CL, Donaldson DD. Interleukin-13: central mediator of allergic asthma. Science 1998;282:2258-2261.
15. Yang M, Hogan SP, Henry PJ, Matthaei KI, McKenzie AN, Young IG, Rothenberg ME, Foster PS. Interleukin-13 mediates airways hyperreactivity through the IL-4 receptor-alpha chain and STAT-6 independently of IL-5 and eotaxin. Am J Respir Cell Mol Biol 2001; 25:522-530.
16. Kuperman DA, Huang X, Koth LL, Chang GH, Dolganov GM, Zhu Z, Elias JA, Sheppard D, Erle DJ. Direct effects of interleukin-13 on epithelial cells cause airway hyperreactivity and mucus overproduction in asthma. Nat Med 2002;8:885-889.
17. Tabata Y, Khurana Hershey GK. IL-13 receptor isoforms: breaking through the complexity. Curr Allergy Asthma Rep 2007;7:338-345.
18. Grünig G, Warnock M, Wakil AE, Venkayya R, Brombacher F, Rennick DM, Sheppard D, Mohrs M, Donaldson DD, Locksley RM, et al. Requirement for IL-13 independently of IL-4 in experimental asthma. Science 1998;282:2261-2263.
19. Taube C, Duez C, Cui ZH, Takeda K, Rha YH, Park JW, Balhorn A, Donaldson DD, Dakhama A, Gelfand EW. The role of IL-13 in established allergic airway disease. J Immunol 2002;169:6482-6489.
20. Wilson MS, Elnekave E, Mentink-Kane MM, Hodges MG, Pesce JT, Ramalingam TR, Thompson RW, Kamanaka M, Flavell RA, Keane- Myers A, et al. IL-13Ra2 and IL-10 coordinately suppress airway inflammation, airway-hyperreactivity, and fibrosis in mice. J Clin Invest 2007;117:2941-2951.
21. Zheng T, Liu W, Oh SY, Zhu Z, Hu B, Homer RJ, Cohn L, Grusby MJ, Elias JA. IL-13 receptor alpha2 selectively inhibits IL-13-induced responses in the murine lung. J Immunol 2008;180:522-529.
22. Starkey MR, Nguyen DH, Essilfie AT, Kim RY, Hatchwell LM, Collison AM, Yagita H, Foster PS, Horvat JC, Mattes J, et al. Tumor necrosis factor-related apoptosis-inducing ligand translates neonatal respiratory infection into chronic lung disease. Mucosal Immunol 2014;7:478-488.
23. Hansbro NG, Horvat JC, Wark PA, Hansbro PM. Understanding the mechanisms of viral induced asthma: new therapeutic directions. Pharmacol Ther 2008;117:313-353.
24. Horvat JC, Beagley KW, Wade MA, Preston JA, Hansbro NG, Hickey DK, Kaiko GE, Gibson PG, Foster PS, Hansbro PM. Neonatal chlamydial infection induces mixed T-cell responses that drive allergic airway disease. Am J Respir Crit Care Med 2007;176: 556-564.
25. Horvat JC, Starkey MR, Kim RY, Phipps S, Gibson PG, Beagley KW, Foster PS, Hansbro PM. Early-life chlamydial lung infection enhances allergic airways disease through age-dependent differences in immunopathology. J Allergy Clin Immunol 2010;125: 617-625.
26. Starkey MR, Kim RY, Beckett EL, Schilter HC, Shim D, Essilfie AT, Nguyen DH, Beagley KW, Mattes J, Mackay CR, et al. Chlamydia muridarum lung infection in infants alters hematopoietic cells to promote allergic airway disease in mice. PLoS One 2012;7: e42588.
27. Starkey MR, Essilfie AT, Horvat JC, Kim RY, Nguyen DH, Beagley KW, Mattes J, Foster PS, Hansbro PM. Constitutive production of IL-13 promotes early-life Chlamydia respiratory infection and allergic airway disease. Mucosal Immunol 2013;6:569-579.
28. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008;26:677-704.
29. Loke P, Allison JP. PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells. Proc Natl Acad Sci USA 2003;100:5336-5341.
30. Fankhauser SC, Starnbach MN. PD-L1 limits the mucosal CD81 T cell response to Chlamydia trachomatis. J Immunol 2014;192: 1079-1090.
31. Akbari O, Stock P, Singh AK, Lombardi V, Lee WL, Freeman GJ, Sharpe AH, Umetsu DT, Dekruyff RH. PD-L1 and PD-L2 modulate airway inflammation and iNKT-cell-dependent airway hyperreactivity in opposing directions. Mucosal Immunol 2010;3:81-91.
32. Kerzerho J, Maazi H, Speak AO, Szely N, Lombardi V, Khoo B, Geryak S, Lam J, Soroosh P, Van Snick J, et al. Programmed cell death ligand 2 regulates TH9 differentiation and induction of chronic airway hyperreactivity. J Allergy Clin Immunol 2013;131:1048-1057, 1057. e1-1057.e2.
33. Lewkowich IP, Lajoie S, Stoffers SL, Suzuki Y, Richgels PK, Dienger K, Sproles AA, Yagita H, Hamid Q, Wills-Karp M. PD-L2 modulates asthma severity by directly decreasing dendritic cell IL-12 production. Mucosal Immunol 2013;6:728-739.
34. Gollwitzer ES, Saglani S, Trompette A, Yadava K, Sherburn R, McCoy KD, Nicod LP, Lloyd CM, Marsland BJ. Lung microbiota promotes tolerance to allergens in neonates via PD-L1. Nat Med 2014;20: 642-647.
35. Matsumoto K, Kan-O K, Eguchi-Tsuda M, Fukuyama S, Asai Y, Matsumoto T, Moriwaki A, Matsunaga Y, Tsutsui H, Kawai T, et al. Essential role of B7-H1 in double-stranded RNA-induced augmentation of an asthma phenotype in mice. Am J Respir Cell Mol Biol 2011;45:31-39.
36. Chen-Yu Hsu A, Starkey MR, Hanish I, Parsons K, Haw TJ, Howland LJ, Barr I, Mahony JB, Foster PS, Knight DA, et al. Targeting PI3Kp110a suppresses influenza virus infection in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2015;191: 1012-1023.
37. Essilfie AT, Horvat JC, Kim RY, Mayall JR, Pinkerton JW, Beckett EL, Starkey MR, Simpson JL, Foster PS, Gibson PG, et al. Macrolide therapy suppresses key features of experimental steroid-sensitive and steroid-insensitive asthma. Thorax 2015; 70:458-467.
38. Horvat JC, Starkey MR, Kim RY, Beagley KW, Preston JA, Gibson PG, Foster PS, Hansbro PM. Chlamydial respiratory infection during allergen sensitization drives neutrophilic allergic airways disease. J Immunol 2010;184:4159-4169.
39. Essilfie AT, Simpson JL, Dunkley ML, Morgan LC, Oliver BG, Gibson PG, Foster PS, Hansbro PM. Combined Haemophilus influenzae respiratory infection and allergic airways disease drives chronic infection and features of neutrophilic asthma. Thorax 2012;67: 588-599.
40. Beckett EL, Phipps S, Starkey MR, Horvat JC, Beagley KW, Foster PS, Hansbro PM. TLR2, but not TLR4, is required for effective host defence against Chlamydia respiratory tract infection in early life. PLoS One 2012;7:e39460.
41. Matsumoto K, Inoue H, Nakano T, Tsuda M, Yoshiura Y, Fukuyama S, Tsushima F, Hoshino T, Aizawa H, Akiba H, et al. B7-DC regulates asthmatic response by an IFN-gamma-dependent mechanism. J Immunol 2004;172:2530-2541.
42. Tsushima F, Iwai H, Otsuki N, Abe M, Hirose S, Yamazaki T, Akiba H, Yagita H, Takahashi Y, Omura K, et al. Preferential contribution of B7-H1 to programmed death-1-mediated regulation of haptenspecific allergic inflammatory responses. Eur J Immunol 2003;33: 2773-2782.
43. Chang WS, Kim JY, Kim YJ, Kim YS, Lee JM, Azuma M, Yagita H, Kang CY. Cutting edge: Programmed death-1/programmed death ligand 1 interaction regulates the induction and maintenance of invariant NKT cell anergy. J Immunol 2008;181:6707-6710.
44. Essilfie AT, Simpson JL, Horvat JC, Preston JA, Dunkley ML, Foster PS, Gibson PG, Hansbro PM. Haemophilus influenzae infection drives IL-17-mediated neutrophilic allergic airways disease. PLoS Pathog 2011;7:e1002244.
45. Preston JA, Thorburn AN, Starkey MR, Beckett EL, Horvat JC, Wade MA, O'Sullivan BJ, Thomas R, Beagley KW, Gibson PG, et al. Streptococcus pneumoniae infection suppresses allergic airways disease by inducing regulatory T-cells. Eur Respir J 2011;37:53-64.
46. Thorburn AN, Foster PS, Gibson PG, Hansbro PM. Components of Streptococcus pneumoniae suppress allergic airways disease and NKT cells by inducing regulatory T cells. J Immunol 2012;188: 4611-4620.
47. Thorburn AN, O'Sullivan BJ, Thomas R, Kumar RK, Foster PS, Gibson PG, Hansbro PM. Pneumococcal conjugate vaccine-induced regulatory T cells suppress the development of allergic airways disease. Thorax 2010;65:1053-1060.
48. Asquith KL, Horvat JC, Kaiko GE, Carey AJ, Beagley KW, Hansbro PM, Foster PS. Interleukin-13 promotes susceptibility to chlamydial infection of the respiratory and genital tracts. PLoS Pathog 2011;7: e1001339.
49. Hansbro PM, Hamilton MJ, Fricker M, Gellatly SL, Jarnicki AG, Zheng D, Frei SM, Wong GW, Hamadi S, Zhou S, et al. Importance of mast cell Prss31/transmembrane tryptase/tryptase-g in lung function and experimental chronic obstructive pulmonary disease and colitis. J Biol Chem 2014;289:18214-18227.
50. Preston JA, Essilfie AT, Horvat JC, Wade MA, Beagley KW, Gibson PG, Foster PS, Hansbro PM. Inhibition of allergic airways disease by immunomodulatory therapy with whole killed Streptococcus pneumoniae. Vaccine 2007;25:8154-8162.
51. Chen W, Tabata Y, Gibson AM, Daines MO, Warrier MR, Wills-Karp M, Hershey GK. Matrix metalloproteinase 8 contributes to solubilization of IL-13 receptor a2 in vivo. J Allergy Clin Immunol 2008;122:625-632.
52. Porcella SF, Carlson JH, Sturdevant DE, Sturdevant GL, Kanakabandi K, Virtaneva K, Wilder H, Whitmire WM, Song L, Caldwell HD. Transcriptional profiling of human epithelial cells infected with plasmid-bearing and plasmid-deficient Chlamydia trachomatis. Infect Immun 2015;83:534-543.
53. Jupelli M, Murthy AK, Chaganty BK, Guentzel MN, Selby DM, Vasquez MM, Mustafa SB, Henson BM, Seidner SR, Zhong G, et al. Neonatal chlamydial pneumonia induces altered respiratory structure and function lasting into adult life. Lab Invest 2011;91:1530-1539.
54. Donaldson DD, Whitters MJ, Fitz LJ, Neben TY, Finnerty H, Henderson SL, O'Hara RM Jr, Beier DR, Turner KJ, Wood CR, et al. The murine IL- 13 receptor a2: molecular cloning, characterization, and comparison with murine IL-13 receptor a1. J Immunol 1998;161:2317-2324.
55. Blausen gallery staff. Blausen gallery 2014. Wikiversity J Med 2014;1:2.
56. Kaiko GE, Phipps S, Hickey DK, Lam CE, Hansbro PM, Foster PS, Beagley KW. Chlamydia muridarum infection subverts dendritic cell function to promote Th2 immunity and airways hyperreactivity. J Immunol 2008;180:2225-2232.